> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Meeting on Neurocrine Bio NDA Canceled
- URL: https://www.fdaweb.com/panel-meeting-on-neurocrine-bio-nda-canceled/
- Published: 2017-01-19T12:00:00.000Z
- Updated: 2026-09-14T22:01:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137775

*Federal Register* Notice: FDA has canceled a 2/16-planned Psychopharmacologic Drugs Advisory Committee meeting that was announced in the 12/27/2016 *Federal Register*. Panel members were scheduled to review a Neurocrine Biosciences NDA for valbenazine 40 milligram (mg) capsules, indicated for treating Tardive Dyskinesia. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-01-19/pdf/2017-01170.pdf?ref=fdaweb.com).